Key result
Advanced glycation end products (AGE-albumin) increased angiogenesis in serum-free conditions but inhibited it in serum-supplemented conditions, indicating microenvironment-dependent effects.
Why the study?
Does AGE-albumin modulate angiogenesis in preclinical models depending on the cellular microenvironment?
Does AGE-albumin modulate angiogenesis in preclinical models depending on the cellular microenvironment?
Advanced glycation end products exert divergent, microenvironment-dependent effects on angiogenesis, which may help explain the complex vascular complications seen in diabetes.
No takes yet. Share an insight, caveat, or question.
Does not support changes in diabetic vascular care; leaves open whether microenvironment-dependent AGE effects translate to human disease.
Devi et al. (2011) studied Angiogenesis in a diabetic state. Advanced glycation end products (AGE-albumin) vs. Serum-supplemented vs serum-free conditions was evaluated on Angiogenic response (sprouting, CD31, E-selectin, and VEGF expression). Advanced glycation end products (AGE-albumin) increased angiogenesis in serum-free conditions but inhibited it in serum-supplemented conditions, indicating microenvironment-dependent effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: